Emergent BioSolutions Inc. (NYSE:EBS) does about 1.53M shares in volume on a normal day but saw 1231509 shares change hands in Friday trading. The company now has a market cap of 265.30M USD . Its current market price is $4.97, marking a decrease of -2.93% compared to the previous close of $5.12. The 52 week high reached by this stock is $28.68 whilst the lowest price level in 52 weeks is $5.01. The script in recent trading has seen the stock touch a high of $5.22 and a low of $4.95.
Emergent BioSolutions Inc. (EBS) has a 20-day trading average at $6.47 and the current price is -82.67% off the 52-week high compared with -0.80% distance from its 52-week low. The 50-day simple moving average of the closing price is $7.33 and its 200-day simple moving average is $10.55. If we look at the stock’s price movements over the week, volatility stands at 5.35%, which increases to 7.31% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 26.52 to suggest the stock is oversold.
3 analysts observing the Emergent BioSolutions Inc. (EBS) stock have set the 12-month price targets for the company’s shares at between $11.00 and $22.00. The consensus objective for the share price is $15.50, suggesting that the stock has a potential upside of 67.94% over the period. The median price target is 63.19% away from the current levels at $13.50.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 10, 2023 when The Benchmark Company upgraded the stock to “Buy” and issued a price target of $22.
The current price level is -24.61%, -32.84%, and -53.26% away from its SMA20, SMA50, and SMA200 respectively, with the EBS price moving above the 50-day SMA on August 18. Emergent BioSolutions Inc. (EBS) stock is down -9.31% over the week and -29.60% over the past month. Its price is -57.92% year-to-date and -82.52% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2023, with the company’s earnings per share (EPS) of -$1.06 below consensus estimates by -$0.57. The company’s next earnings report is expected on 11/02/2023, with forecasts estimating quarterly EPS at $0.26 and -$1.77 for whole year. EBS’s earnings per share are forecast to grow by 20.60% this year and 119.80% over next year. Expected sales for next quarter are $411.93 million, which analysts say will come at $1.13 billion for the current fiscal year and next year at $1.21 billion. In addition, estimates put the company’s current quarterly revenue at an average of $291.43 million.
To reach the target analysts have set, the stock logically needs to grow 67.94 percent from here.
Outstanding shares total 50.70M with insiders holding 2.29% of the shares and institutional holders owning 93.27% of the company’s common stock. The company has a return on investment of -6.30% and return on equity of -48.70%. The forward price to earnings ratio is 14.00. The beta has a value of 0.90. Price to book ratio is 0.26 and price to sales ratio is 0.25.
